Identification of therapeutic targets and treatments for Alzheimer's, Parkinson's and other neurodegenerative diseases. This research encompasses target validation, in vitro assay development and optimization, high-throughput compound screening (HTS), and in vivo compound assessment, including pharmacokinetic and pharmacodynamic analyses, safety pharmacology and efficacy testing in neurodegenerative disease models. In addition, we conduct translational research studies to identify new potential drug targets for these neurodegenerative diseases.
Investigator: Kurt R. Brunden, PhD